Heart Test Laboratories, Inc.

Equities

HSCS

US42254E3027

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
4.03 ^USD	-0.74%		-4.95%	-76.43%

07-11	Heart Test Laboratories, Inc. Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction	CI
04-24	HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG	CI

Thinking about buying stock in Exela Technologies, Genius Group, Aethlon Medical, G Medical Innovations, or Heart Test Laboratories?

January 30, 2023 at 10:50 am

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, GNS, AEMD, GMVD, and HSCS.

InvestorsObserver (PRNewsfoto/InvestorsObserver)

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

XELA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=XELA&prnumber=013020234
GNS: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=GNS&prnumber=013020234
AEMD: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=AEMD&prnumber=013020234
GMVD: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=GMVD&prnumber=013020234
HSCS: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=HSCS&prnumber=013020234

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-exela-technologies-genius-group-aethlon-medical-g-medical-innovations-or-heart-test-laboratories-301733534.html

SOURCE InvestorsObserver

Latest news about Heart Test Laboratories, Inc.

Heart Test Laboratories, Inc. Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction	07-11	CI
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG	04-24	CI
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients	03-26	CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	03-14	CI
Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board	02-26	CI
Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board	02-12	CI
HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board	02-01	CI
Heart Test Laboratories, Inc. has Changed its Name to HeartSciences Inc	01-17	CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	12-14	CI
Heart Test Laboratories, Inc. announced that it has received $0.934997 million in funding	12-06	CI
Heart Test Laboratories, Inc. announced that it has received $1.085006 million in funding	12-06	CI
Heart Test Laboratories, Inc. Enters into Multiple Definitive License Agreements with Icahn School of Medicine At Mount Sinai	12-06	CI
HeartSciences Completes License Agreements on AI Cardiovascular Algorithms With Icahn School of Medicine at Mount Sinai	11-20	MT
Heart Test Laboratories, Inc. announced that it expects to receive $0.934997 million in funding	11-15	CI
Heart Test Laboratories, Inc. announced that it expects to receive $1.085006 million in funding	11-14	CI
Heart Test Laboratories, Inc. Announces That Its Myovista® Wavecgtm Has Been Selected by Cardiact Ltd (?Cardiact?) to Be Used in Its Heart Screening Program of Members of the Association of Garda Sergeants and Inspectors	11-13	CI
Heart Test Laboratories, Inc. announced that it has received $1 million in funding	23-09-19	CI
Sector Update: Health Care Stocks Lower Late Afternoon	23-09-18	MT
Sector Update: Health Care Stocks Mixed Monday Afternoon	23-09-18	MT
Heart Test Laboratories Files for $50 Million Mixed Shelf; Shares Drop	23-09-18	MT
Heart Test Laboratories, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-14	CI
Heart Test Laboratories, Inc. announced that it expects to receive $1 million in funding	23-09-06	CI
Heart Test Laboratories Has Distribution Accord With Denmark's FJ Medical	23-08-31	MT
Heart Test's MyoVista wavECG Selected by PanaceaFlo for Heart Screening Evaluation Study in Dublin	23-08-24	MT
Heart Test Laboratories, Inc. Announces It?s MyoVista wavECGTM Selection to Be Used in Irish Heart Screening Evaluation	23-08-24	CI

Chart Heart Test Laboratories, Inc.

Duration

Period

More charts

Company Profile

Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Companyâs initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the MyoVista is an ECG that can be used in a range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, MyoVista provides conventional ECG information. The Company focuses on marketing its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacturing the devices using outsourced production facilities.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-16 - Q4 2024 Earnings Release (Projected)

More about the company